• Imexpharm sets a record for revenue and profit growth, confirming its leadership position in
the industry
• IMP4 goes into operation and IMP2 successfully renews its EU-GMP compliance status for the
second time; IMP3 renews its status for the third time
• Imexpharm has 11 registration numbers for 6 products in Europe, bringing the total number of
EU MAs to 27 for 11 products
• Imexpharm becomes the leading domestic pharmaceutical company in the ETC channel
• The company ranks number one in the Vietnamese antibiotics market, including both foreign
and domestic suppliers